Pharmacological approaches to preserving and restoring coronary endothelial function

Bibliography

• MONCADA S, PALMER RMJ, HIGGSEA: NO: physiology, pathophysiology and pharmacology. Pharmacol Rev (1991) 43:109–142.
   PubMed Web of Science ®Google Scholar
• DUFFY SJ, CASTLE SF, HARPER RW,MEREDITH IT: Contribution of vasodilator prostanoids and NO to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation (1999) 100:1951–1957.
   PubMed Web of Science ®Google Scholar
• WOODMAN OL, DUSTING GJ: N-nitro-L-arginine causes coronary vasoconstriction and inhibits endothelium dependent vasodilatation in anaesthetized greyhounds. Br j Pharmacol (1991) 103:1407–1410.
   PubMed Web of Science ®Google Scholar
• IGNARRO LJ, CIRINO G, CASINI A, NAPOLI C: NO as a signalling molecule in the vascular system: an overview. j Cardiol. Pharmacol (1999) 34:879–886.
   PubMed Web of Science ®Google Scholar
• GARLAND CJ, PLANE F, KEMP BK, COCKS TM: endothelium dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Li. (1995) 16:23–30.
   PubMed Web of Science ®Google Scholar
• NAJIBI S, COWAN CL, PALACINO JC, COHEN RA: Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am. J. Physiol (1994) 266:h2061–h2067.
   Google Scholar
• CHAN ECH, WOODMAN OL: Enhanced role for the opening of potassium channels in relaxant responses to acetylcholine after myocardial ischaemia and reperfusion in dog coronary arteries. Br Pharmacol (1999) 126:925–932.
   PubMed Web of Science ®Google Scholar
• PACOLD I, HWANG MH, LAWLESS CE, DIAMOND P, SCANLON PJ, LOEB HS: Effects of indomethacin on coronary haemodynamics, myocardial metabolism and anginal threshold in CAD. Am. Cardiol (1986) 57:912–915.
   PubMed Web of Science ®Google Scholar
• LAMPING KG, NUNO DW, SHESELYEG, MAEDA N, FARACI FM: Vasodilator mechanisms in the coronary circulation of endothelial NO synthase-deficient mice. Am. J. Physiol (2000) 279:h1906–h1912.
   Google Scholar
• MACCARTHY PA, PEGGE NC, PRENDERGAST BD, SHAH AM, H GP: The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. j Am. Coll. Cardiol (2001) 37:137–143.
   PubMed Web of Science ®Google Scholar
• •Evidence that basal endothelin modulates the tone of angiographically normal coronary arteries.
   Google Scholar
• THORIN E, PARENT R, MING Z, LAVALLEE M: Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. Am. j Physiol (1999) 277:h524–h532.
   Google Scholar
• MOMBOULI JV, VANHOUTTE PM: Endothelial dysfunction: from physiology to therapy. j Ma Cell. Cardiol (1999) 31:61–74.
   PubMed Web of Science ®Google Scholar
• SCHACHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 101:1899–1906.
   PubMed Web of Science ®Google Scholar
• •Clinical evidence that impaired endothelium-dependent coronary vasodilatation predicts long-term adverse cardiovascular events.
   Google Scholar
• QUYYUMI AA, DAKAK N, ANDREWS NP et al.: NO activity in the coronary circulation impact of risk factors for coronary atherosclerosis. j Chit. Invest. (1995) 95:1747–1755.
   PubMed Web of Science ®Google Scholar
• DART AM, CHIN-DUSTING JPF: Lipidsand the endothelium. Cardiovasc. Res. (1999) 43:308–322.
   PubMedGoogle Scholar
• ZEIHER AM, DREXLER H, WOLLSCHLAGER H, JUST H: Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation (1991) 83:391–401.
   PubMed Web of Science ®Google Scholar
• SIMON BC, CUNNINGHAM LD, COHEN RA: Oxidized low density lipoproteins cause contraction and inhibit endothelium dependent relaxation in the pig coronary artery. j Chit. Invest. (1990) 86:75–79.
   PubMed Web of Science ®Google Scholar
• RAITAKARI OT, PITKANEN OP, LEHTIMAKI T et al.: In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. j Am. Coll. Cardiol. (1997) 30:97–102.
   PubMed Web of Science ®Google Scholar
• KUHN FE, MOHLER ER, SATLER LF, REAGAN K, LU DY, RACKLEY CE: Effects of high-density lipoprotein on acetylcoline-induced coronary vasoreactivity. Am. I Cardiol (1991) 68:1425–1430.
   PubMed Web of Science ®Google Scholar
• SOBEY CG, WOODMAN OL: Myocardial ischaemia: what happens to the coronary arteries? Trends Pharmacol. Sci. (1993) 14:448–453.
   Google Scholar
• VINTEN-JOHANSEN J, ZHAO ZQ, NAKAMURA M et al: NO and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann. NY Acad. Sci. (1999) 874:354–370.
   PubMed Web of Science ®Google Scholar
• HARRISON DG: Cellular and molecularmechanisms of endothelial cell dysfunction. Chit. Invest. (1997) 100:2153–2157.
   PubMed Web of Science ®Google Scholar
• GOUMOS G, TENTOLOURIS C, TOUSOULIS D, STEFANADIS C, TOUTOUZAS P: Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis (2001) 154:255–267.
   PubMed Web of Science ®Google Scholar
• •Review of the use of L-arginine to improve endothelial release of NO.
   Google Scholar
• BODE-BOGER SM, BOGER RH, CREUTZIG A et al.: L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Chit. Sci. (1994) 87:303–310.
   Google Scholar
• KAYE DM, AHLERS BA, AUTELITANO DJ, CHIN-DUSTING JPF: In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation (2000) 102:2707–2712.
   PubMed Web of Science ®Google Scholar
• ADAMS MR, MCCREDIE R, JESSUP W, RONBINSON J, SULLIVAN D, CELERMAJER DS: Oral 1-arginine improves endothelium dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with CAD. Atherosclerosis (1997) 129:261–269.
   PubMed Web of Science ®Google Scholar
• BLUM A, HATHAWAY L, MINCEMOYER R et al.: Oral L-arginine in patients with CAD on medical management. Circulation (2000) 101:2160–2164.
   PubMed Web of Science ®Google Scholar
• COHEN G, BORGER MA, WEISEL RD,RAO V: Intraoperative myocardial protection: current trends and future perspectives. Ann. Thoracic Surg. (1999) 68:1995–2001.
   PubMed Web of Science ®Google Scholar
• WALLACE AW, RATCLIFFE MB, GALINDEZ D, KONG JS: L-arginine infusion dilates coronary vasculature in patients undergoing coronary bypass surgery. Anesthesiology (1999) 90:1577–1586.
   PubMed Web of Science ®Google Scholar
• BLUMENTHAL RS, ZACUR HA, REIS SE, POST WS: Beyond the null hypothesis - do the hers results disprove the estrogen/ coronary heart disease hypothesis? Am. Cordial. (2000) 85:1015–1017.
   PubMed Web of Science ®Google Scholar
• •Discussion of trials investigating the effect of hormone replacement therapy on CAD.
   Google Scholar
• MENDELSOHN ME: Nongenomic, estrogen receptor-mediated activation of endothelial NO synthase. how does it work? what does it mean? Circ. Res. (2000) 87:677–682.
   Google Scholar
• •Brief review of the possible mechanisms involved in the effects of oestrogen on vascular function.
   Google Scholar
• TEOH H, LEUNG SWS, MAN RYK: Short-term exposure to physiological levels of 1 713-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc. Res. (1999) 42:224–231.
   PubMed Web of Science ®Google Scholar
• GILLIGAN DM, QUYYUMI AA, CANNON RO, JOHNSON GB, SCHENKE WH: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation (1994) 89:2545–2551.
   PubMed Web of Science ®Google Scholar
• BLUM A, CANNON RO: Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function. Curr. Opin Lipidol (1998) 9:575–586.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JK, HONORE EK, WASHBURN SA, CLARKSON TB: Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. I Am. Coll. Cordial. (1994) 24:1757–1761.
   PubMed Web of Science ®Google Scholar
• JUN SS, CHEN Z, PACE MC, SHAUL PW: Estrogen upregulates cyclo-oxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. I Chit. Invest. (1998) 102:176–183.
   Google Scholar
• MENDELSOHN ME, KARAS RH: Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. N Engl. I Med. (1999) 340:1801–1811.
   PubMed Web of Science ®Google Scholar
• BINKO J, MAJEWSKI H: 1713-estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible nos. Am. J. Physiol (1999) 274:h853–h859.
   Google Scholar
• HERRINGTON DM, REBOUSSIN DM, BROSNIHAN KB et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl. I Med. (2000) 343:522–529.
   PubMed Web of Science ®Google Scholar
• HULLEY S, GRADY D, BUSH T et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. j Am. Med. Assoc. (1998) 280:605–613.
   PubMed Web of Science ®Google Scholar
• KIM YD, CHEN B, BEAUREGARD J et al.: 1713-estradiol prevents dysfunction of canine coronary epithelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation (1996) 94:2901–2908.
   PubMed Web of Science ®Google Scholar
• MOORADIAN AD: Antioxidant properties of steroids. j Steroid Biochem. Ma Biol. (1993) 45:509–511.
   PubMed Web of Science ®Google Scholar
• NODE K, KITAKAZE M, KOSAKA H, MINAMINO T, FUNAYA H, HORI M: Amelioration of ischemia- and reperfusion-induced myocardial injury by 17P-estradiol: role of NO and calcium-activated potassium channels. Circulation (1997) 96: 1953-1963.
   Google Scholar
• FRASER H, DAVIDGE ST, CLANACHAN AS: Activation of Ca2+-independent NO synthase by 1 713-estradiol in post-ischemic rat heart. Cardiovasc. Res. (2000) 46:111–118.
   PubMed Web of Science ®Google Scholar
• DAVIGNON J, LAAKSONEN R: Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol (1999) 10:543–559.
   PubMed Web of Science ®Google Scholar
• LEFER AM, SCALIA R, LEFER DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. (2001) 49:281–287.
   PubMed Web of Science ®Google Scholar
• •Review of the vascular actions of the statins that are unrelated to lipid-lowering.
   Google Scholar
• EGASHIRA K, HIROOKA Y, KAI H etal.: Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation (1994) 89:2519–2524.
   Google Scholar
• TREASURE CB, KLEIN JL, WEINTRAUB WS et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with CAD. N. Engl. J. Med. (1995) 332:481–487.
   PubMed Web of Science ®Google Scholar
• O'DRISCOL G, GREEN D, TAYLOR RR: Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 95:1126–1131.
   PubMed Web of Science ®Google Scholar
• LIAO JK: Endothelium and acute coronarysyndromes. Chit. Chem. (1998) 44:1799–1808.
   Google Scholar
• LAUFS U, LA FATA V, LIAO JK: Inhibition of 3-hydroxy-3-methylglutaryl (hmg)-coa reductase blocks hypoxia-mediated down-regulation of endothelial NO synthase. I Biol. Chem. (1997) 50:31725–31729.
   Google Scholar
• ENDRES M, LAUFS U, HUANG Z et al:Stroke protection by 3-hydroxy-3-methylglutaryl (hmg)-coa reductase inhibitors mediated by endothelial NO synthase. Proc. Natl. Acad. Sci. USA (1998) 95:8880–8885.
   PubMed Web of Science ®Google Scholar
• DI NAPOLI P, TACCARDI AA, GRILLI Aet al: Simvastatin reduces reperfusion injury by modulating NO synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc. Res. (2001) 51:283–293.
   PubMed Web of Science ®Google Scholar
• LEFER AM, CAMPBELL B, SHIN YK, SCALIA R, HAYWARD R, LEFER DJ: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation (1999) 100:178–184.
   PubMed Web of Science ®Google Scholar
• MOGHADASIAN MH, MANCINI GBJ, FROHLICH JJ: Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother. (2000) 1:683–695.
   PubMedGoogle Scholar
• MANCINI GBJ, HENRY GC, MACAYA C etal.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with CAD: the TREND (Trial On 1773 Reversing Endothelial Dysfunction) study. Circulation (1996) 94:258–265.
   Google Scholar
• SCHLAIFER JD, WARGOVICH TJ, O'NEILL BJ et al.: Effects of quinapril on coronary blood flow in CAD patients with endothelial dysfunction. Am. j Cardial. (1997) 80:1594–1597.
   Google Scholar
• HORNIG B, LANDMESSER U, KOHLER C et al: Comparitive effect of ACE inhibition and angiotensin II Type 1 receptor antagonism on bioavailability of NO in patients with CAD: role of superoxide dismutase. Circulation (2001) 103:799–805.
   PubMed Web of Science ®Google Scholar
• •Clinical evidence that endothelial function is improved by ACEIs and AT1 receptor antagonists.
   Google Scholar
• LINZ W, WIEMER G, GOHLKE P, UNGER T, SCHOLKENS BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacy]. Rev. (1995) 47:25–49.
   PubMed Web of Science ®Google Scholar
• GOHLKE P, PEES C, UNGER T: AT2 receptor stimulation increases aortic cyclic gmp in shrsp by a kinin-dependent mechanism. Hypertension (1998) 31:349–355.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, KURZ S, MUNZEL T et al.: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane nadtil nadph oxidase activation: contribution to alterations of vasomotor tone. j OM. Invest. (1996) 97:1916–1923.
   PubMed Web of Science ®Google Scholar
• ORN S, DICKSTEIN K: Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opiri. Pharmacother. (2000) 1:1105–1116.
   PubMedGoogle Scholar
• PIANA RN, WANG SY, FRIEDMAN M, SELLKE FW: Angiotensin-converting enzyme inhibition preserves endothelium dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation (1996) 93:544–551.
   PubMed Web of Science ®Google Scholar
• BARSOTTI A, DI NAPOLI P, TACCARDI AA etal.: Mk-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mrna overexpression after global ischaemia. Atherosclerosis (2001) 155:53–59.
   Google Scholar
• SCHNEIDER CA, VOTH E, MOKA D et al.: Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat iv: a study using[1501 water dobutamine stress positron emission tomography j Am. Coll. Cardial (1999) 34:1005–1011.
   PubMed Web of Science ®Google Scholar
• GOTO K, FUJII K, ONAKA U, ABE I, FUJISHIMA M: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension (2000) 36:575–580.
   PubMed Web of Science ®Google Scholar
• PIEPER GM, SIEBENEICH W: Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur. Pharmacy]. (2000) 403:129–132.
   PubMed Web of Science ®Google Scholar
• SANZ M, GANADO P, RUIZ E, TEJERINA T: Effect of trandolapril on vascular responsiveness in cholesterol-fed rabbit-isolated arteries. Eur. j Pharmacy]. (2000) 397:359–365.
   PubMed Web of Science ®Google Scholar
• KOH la, BUI MN, HATHAWAY L etal.: Mechanism by which quinapril improves vascular function in CAD. Am. j Cardial (1999) 83:327–331.
   Google Scholar
• •Clinical evidence that ACEIs can reduce oxidant stress.
   Google Scholar
• PRASAD A, HUSAIN S, QUYYUMI AA: Effect of enalaprilat on NO activity in CAD. Am. J. Cordial., (1999) 84:1–6.
   PubMed Web of Science ®Google Scholar
• •Evidence that an ACEI increases NO activity in patients with atherosclerosis.
   Google Scholar
• CHEETHAM C, COLLIS J, O'DRISCOLL G, STANTON K, TAYLOR R, GREEN D: Losartan, an angiotensin Type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. j Am. Coll Cardial (2000) 36:1461–1466.
   PubMed Web of Science ®Google Scholar
• CHEETHAM C, O'DRISCOLL G, STANTON K, TAYLOR R, GREEN D: Losartan, an angiotensin Type 1 receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Li. (2001) 100:13–17.
   Google Scholar
• VARIN R, MULDER P, TAMION F et al: Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of NO, prostanoids, oxidant stress, and bradykinin. Circulation (2000) 102:351–356.
   PubMed Web of Science ®Google Scholar
• CAI H, HARRISON DG: Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ. Res. (2000) 87:840–844.
   PubMed Web of Science ®Google Scholar
• RUBINO R, BURNSTOCK G: Recovery after dietary vitamin e supplementation of impaired endothelial function in vitamin E-deficient rats. Br. j Pharmacy]. (1994) 112:515–518.
   PubMed Web of Science ®Google Scholar
• HEITZER T, HERTTUALA SY, WILD E, LUOMA J, DREXLER H: Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolaemia, chronic smoking or both. J. Am. Coll. Cardial (1999) 33:499–505.
   PubMed Web of Science ®Google Scholar
• •Evidence that long term use of a-tocopherol improves endothelium-dependent vasodilatation.
   Google Scholar
• NEUNTEUFL T, PRIGLINGER U, HEHER S et al.: Effercts of vitamin E on chronic and acute endothelial dysfunction in smokers. j Am. Coll Cardial (2000) 35:277–283.
   PubMed Web of Science ®Google Scholar
• MOTOYAMA T, KAWANO H, KUGIYAMA K et al.: Vitamin E administration improves impairment of endothelium dependent vasodilation in patients with coronary spastic angina. J. Am. Coll Cardial (1998) 32:1672–1679.
   PubMed Web of Science ®Google Scholar
• BROWN AA, HU FB: Dietary modulationof endothelial function: implications for cardiovascular disease. Am. j Clin. Nutr. (2001) 73:673–686.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the potential for dietary supplements to modulate endothelial function.
   Google Scholar
• TRIBBLE DL: Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin c, vitamin E, and 13-carotene. Circulation (1999) 99:591–595.
   PubMed Web of Science ®Google Scholar
• •Recommendations from the American Heart Association regarding the use of anti-oxidants.
   Google Scholar
• INVESTIGATORS H: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl. I Med. (2000) 342:154–160.
   PubMedGoogle Scholar
• CARR AC, ZHU BZ, FREI B: Potentialantiatherogenic mechanisms of ascorbate (vitamin C) and a-tocopherol (vitamin EL Circ. Res. (2000) 87:349–354.
   Google Scholar
• SOLZBACH U, HORNIG B, JESERICH M, JUST H: Vitamin c improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation (1997) 96:1513–1519.
   PubMed Web of Science ®Google Scholar
• KUGIYAMA K, MOTOYAMA T, HIRASHIMA 0 et al.: Vitamin c attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. I Am. Coll Cardial (1998) 32:103–109.
   Google Scholar
• HELLER R, MUNSCHER-PAULIG F, GRABNER R, TILL U: L-ascorbic acid potentiates NO synthesis in endothelial cells. j Biol. Chem. (1999) 274:8254–8260.
   PubMed Web of Science ®Google Scholar
• CARR AC, FRET B: Toward a recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am. J. OM. Nutr. (1999) 69:1086–1107.
   PubMed Web of Science ®Google Scholar
• JANERO DR, EWING JF: NO and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Rad. Biol. Med. (2000) 29:1199–1221.
   PubMed Web of Science ®Google Scholar